The Patent Finder

Targeting PAX2 for the Induction of DEFB1-MEDIATED Tumor Immunity and Cancer Therapy

Phigenix, Inc.

A patent family: one line of work, grouped by real continuity rather than by a technology label inferred from titles. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
PatentTitleHolderStatusExpiresTime remainingConfidence
US 8,735,365Targeting PAX2 for the Induction of DEFB1-MEDIATED Tumor Immunity and Cancer Therapy
In force
 · Medium confidence
Musc Foundation for Research DevelopmentIn force
Medium confidence
US 7,964,577Targeting PAX2 for the Induction of DEFB1-MEDIATED Tumor Immunity and Cancer Therapy
In force
 · High confidence
Phigenix, Inc.In force
High confidence
US 8,623,617Detecting PAX2 for the Diagnosis of Breast Cancer
In force (reinstated)
 · Medium confidence
Musc Foundation for Research DevelopmentIn force (reinstated)
Medium confidence
US 8,722,367Detecting PAX2 for the Diagnosis of Breast Cancer
In force
 · Medium confidence
Musc Foundation for Research DevelopmentIn force
Medium confidence
US 8,431,546Targeting PAX2 for the Induction of DEFB1-MEDIATED Tumor Immunity and Cancer Therapy
Lapsed Apr 30, 2025 on the fee record
Ended Apr 30, 2025 · High confidence
Musc Foundation for Research DevelopmentLapsed Apr 30, 2025 on the fee recordEnded Apr 30, 2025
High confidence
US 8,445,444Compositions and Methods for Diagnosing, Treating, and Preventing Prostate Conditions
Lapsed May 21, 2025 on the fee record
Ended May 21, 2025 · Medium confidence
Musc Foundation for Research DevelopmentLapsed May 21, 2025 on the fee recordEnded May 21, 2025
Medium confidence
US 8,461,101Targeting PAX2 for the Treatment of Breast Cancer
Lapsed Jun 11, 2025 on the fee record
Ended Jun 11, 2025 · High confidence
Musc Foundation for Research DevelopmentLapsed Jun 11, 2025 on the fee recordEnded Jun 11, 2025
High confidence
US 8,461,126Targeting EN2, PAX2, And/Or DEFB1 for Treatment of Prostate Conditions
Lapsed Jun 11, 2025 on the fee record
Ended Jun 11, 2025 · High confidence
Musc Foundation for Research DevelopmentLapsed Jun 11, 2025 on the fee recordEnded Jun 11, 2025
High confidence
US 8,633,149Targeting PAX2 for the Treatment of Breast Cancer
Lapsed Jan 21, 2026 on the fee record
Ended Jan 21, 2026 · High confidence
Musc Foundation for Research DevelopmentLapsed Jan 21, 2026 on the fee recordEnded Jan 21, 2026
High confidence
US 8,080,534Targeting PAX2 for the Treatment of Breast Cancer
Term ended
Term ended Oct 16, 2026 · High confidence
Phigenix, Inc.Term endedTerm ended Oct 16, 2026
High confidence
16 more patents in this group · Pro
10 of 26 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Pro members see all 26, including 11 expired and 4 expiring within the 18 months from Nov 17, 2026.
Upgrade to Pro
1 of these is in force and held by Phigenix, Inc..
Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited